UniProt: P34896 (GLYC_HUMAN); gene SHMT1 (HGNC:10850); 483 aa; chromosome 17p11.2.
EC 2.1.2.1. Cytosolic isozyme (paralog of mitochondrial SHMT2/P34897).
SHMT1 is the cytosolic, PLP-dependent serine hydroxymethyltransferase. The
central reaction is the reversible interconversion of L-serine + THF with glycine
+ 5,10-methylene-THF (Rhea:RHEA:15481; EC 2.1.2.1), the major source of one-carbon
units in the cytosol for thymidylate and purine synthesis and for the methylation
cycle.
"Pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the reversible
conversion of serine and tetrahydrofolate (THF) to glycine and 5,10-methylene
THF, serving as a critical component of the folate cycle and facilitating
one-carbon biosynthetic reactions essential for methionine, purine, and
pyrimidine synthesis" [file:human/SHMT1/SHMT1-uniprot.txt FUNCTION].
Catalytic activity (authoritative Rhea in UniProt):
(6R)-5,10-methylene-5,6,7,8-tetrahydrofolate + glycine + H2O = (6S)-5,6,7,8-tetrahydrofolate + L-serine; EC=2.1.2.1
[file:human/SHMT1/SHMT1-uniprot.txt CATALYTIC ACTIVITY].
Cofactor: pyridoxal 5'-phosphate, bound via Schiff base at Lys-257
[file:human/SHMT1/SHMT1-uniprot.txt COFACTOR; FT BINDING].
Quaternary structure: homotetramer ("dimer of dimers"); crystal structure 1BJ4
PMID:9753690.
Rat-liver work established the tetramer with 4 mol PLP/mol enzyme
[PMID:3110140 "showed a Mr value of 220,000 on gel filtration, indicating a
tetrameric structure"; PMID:6795186 "each of the isozymes is composed of 4
identical polypeptide chains"].
Pathway (UniProt): "One-carbon metabolism; tetrahydrofolate interconversion";
also "Amino-acid degradation" (via HTMLA/threonine-aldolase side activities)
[file:human/SHMT1/SHMT1-uniprot.txt PATHWAY].
SHMT1, like other fold-type-I PLP aldolases, cleaves several 3-hydroxy amino
acids by retro-aldol:
- L-allo-threonine, L-threonine → glycine + acetaldehyde
- 3-phenylserine → glycine + benzaldehyde (by similarity, P35623)
- HTML (3-hydroxy-N6,N6,N6-trimethyl-L-lysine) → glycine + 4-(trimethylamino)butanal
(the second, "missing" step of carnitine biosynthesis; HTMLA activity)
[file:human/SHMT1/SHMT1-uniprot.txt CATALYTIC ACTIVITY].
Carnitine/HTMLA activity was demonstrated experimentally in PMID:38615009 (OSMES
docking + biochemical validation): "the top-ranked candidates, serine
hydroxymethyl transferase (SHMT) 1 and 2, catalyze the HTMLA reaction"; a
kcat/Km of 32.17 s-1 M-1 was measured for SHMT1 on HTML. The paper explicitly
frames this as partial compensation for a lost gene: "HTMLA activity of SHMT
partially compensating for its function" PMID:38615009. So SHMT1's carnitine
role is a low-efficiency moonlighting/backup activity, not a dedicated function.
The threonine-aldolase activities (GO:0004793, GO:0008732) share the same active
site and are genuine but promiscuous.
SHMT1 (and the cytosolic SHMT2α splice form) translocate to the nucleus, where
SHMT1 acts as a scaffold anchoring the de novo thymidylate synthesis complex
(SHMT1 + DHFR + TYMS) to the nuclear lamina (LMNB1) at replication forks
[PMID:22235121 "SHMT serves as scaffold protein that is essential for complex
formation"; "de novo thymidylate biosynthesis occurs at replication forks"].
This is IDA-supported (interaction with TYMS, DHFR, LMNB1; lamin binding
GO:0005521; replication fork GO:0005657). Nuclear import is SUMO-dependent
(SUMOylation at Lys-38/39 by UBC9) PMID:17446168.
PMID:30035852 showed the catalytic activity (not just scaffolding/oligomeric
state) is required for de novo nuclear dTMP synthesis in lung cancer cells:
"de novo thymidylate synthesis requires SHMT1 to be active, regardless of its
oligomeric state". Nuclear translocation is RAN-dependent and independent of
oligomeric state / catalysis [file:human/SHMT1/SHMT1-uniprot.txt SUBCELLULAR LOCATION].
Both nuclear thymidylate function and the moonlighting scaffold/lamin-binding
role are well-supported but represent a specialized, non-core (cell-cycle /
proliferation-context) deployment of the enzyme rather than its evolved core
catalytic function. Treated as KEEP_AS_NON_CORE.
SHMT1 is an mRNA-binding protein. It binds its own 5'-UTR and represses its own
translation PMID:10995219.
The riboregulation was later structurally characterized: RNA binding acts as an
allosteric switch that selectively inhibits the serine-cleavage direction and
promotes glycine→serine conversion, feeding THF/serine to mitochondrial SHMT2
PMID:38996576. This is a well-supported moonlighting/regulatory function; the mRNA
5'-UTR binding (GO:0048027), translation repressor activity (GO:0000900) and
negative regulation of translation (GO:0017148) IDA annotations are kept as
non-core.
protein binding (GO:0005515) IPI annotations are uninformative;identical protein bindingsmall molecule binding (GO:0036094, IPI with CHEBI:67016 =Secondary (non-core but real): nuclear de novo thymidylate synthesis / scaffold
(dTMP biosynthetic process GO:0006231, lamin binding), riboregulation / mRNA
5'-UTR binding, and HTMLA/threonine-aldolase promiscuous activities (carnitine
biosynthesis backup).